Thalidomide-induced neuropathy

Chaudhry, Vinay; Cornblath, David R.; Corse, Andrea M.; Freimer, Miriam; Simmons-O’Brien, Eva; Vogelsang, Georgia B.

doi:10.1212/01.wnl.0000037480.59194.85

Cited by 180 publications

(100 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 It is increasingly recognized that BIPN may be a proteasome inhibitor class effect and that autoimmune factors and inflammation may also trigger BIPN. 2,3,9,10 To our knowledge, only one full paper published to date describes neurophysiologic and pathologic findings after bortezomib administration in animal models. 11 In this study, spinal cord was morphologically normal.…”

Section: Pathogenesis Of Peripheral Neuropathymentioning

confidence: 99%

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

Argyriou

Iconomou

Kalofonos

2008

Blood

376

290

View full text Add to dashboard Cite

Section: Pathogenesis Of Peripheral Neuropathymentioning

confidence: 99%

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

Argyriou

Iconomou

Kalofonos

2008

Blood

376

290

View full text Add to dashboard Cite

“…Clinical data were classified according to the Total Neuropathy Scale (TNS) [18,19] using the clinical version (TNSc) [20] and the reduced version (TNSr), incorporating neurophysiological measures [21] with severity rankings of 0 (none) to 4 (very severe), as previously validated in patients with chemotherapy-induced neuropathy [21,22]. Patients' descriptions of symptoms were staged using the Neuropathy Symptom Score (NSS) into negative (subset IIA) and positive (subset IIB) sensory symptoms summed to give a composite score out of 5 [23].…”

Section: Clinical Assessment: Grading Of Neurotoxicitymentioning

confidence: 99%

Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility

et al. 2011

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Define the symptoms of sensory neurotoxicity in oxaliplatin-treated patients and identify the long-term natural history of nerve dysfunction as a long-lasting complication of treatment that does not necessarily resolve within 6 months.2. Use sensory excitability techniques to predict long-standing changes in sensory nerve function produced by oxaliplatin.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTObjectives. Oxaliplatin-induced neuropathy is a significant and dose-limiting toxicity that adversely affects quality of life. However, the long-term neurological sequelae have not been adequately described. The present study aimed to describe the natural history of oxaliplatin-induced neuropathy, using subjective and objective assessments. The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Methods. From a population of 108 oxaliplatin-treated Symptom Management and Supportive CareThe Oncologist 2011;16:708 -716 www.TheOncologist.com Results. At follow-up, 79.2% of patients reported residual neuropathic symptoms, with distal loss of pinprick sensibility in 58.3% of patients and loss of vibration sensibility in 83.3% of patients. Symptom severity scores were significantly correlated with cumulative dose. There was no recovery of sensory action potential amplitudes in upper and lower limbs, consistent with persistent axonal sensory neuropathy. Sensory excitability parameters had not returned to baseline levels, suggesting persisting abnormalities in nerve function. The extent of excitability abnormalities during treatment was significantly correlated with clinical outcomes at follow-up.Conclusions. These findings establish the persistence of subjective and objective deficits in oxaliplatin-treated patients post-oxaliplatin, suggesting that sensory neuropathy is a long-term outcome, thereby challenging the literature on the reversibility of oxaliplatin-induced neuropathy. The Oncologist 2011;16:708 -716

show abstract

“…Several trials have demonstrated that PN was more likely to appear with a high cumulative dose and that it aggravates with the highest administered doses. [47][48][49][50] A few studies have suggested a lower risk of PN with low doses. In two successive trials, Rajkumar et al reported PN in 50-80% of the patients, and this was correlated with the dose and duration of treatment.…”

Section: Incidence Severity and Risk Factors Of Thalidomide-induced mentioning

confidence: 99%

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

Mohty

El-Cheikh²,

Yakoub-Agha³

et al. 2010

Haematologica

151

137

View full text Add to dashboard Cite

haematologica | 2010; 95 (2) 311In multiple myeloma, peripheral neuropathy has for a long time been considered as mainly secondary to the plasma cell dyscrasia itself. With the advent of new targeted drugs such as thalidomide and bortezomib, the iatrogenic neurotoxicity has become the leading cause of peripheral neuropathy. This review discusses the pathogenesis, incidence, risk factors, diagnosis, characteristics, and management of peripheral neuropathy related to new multiple myeloma drugs, mainly bortezomib and thalidomide. The current knowledge of the pathophysiology of the new forms of peripheral neuropathy is still limited. The mechanisms involved depend on the agents used, patient's medical history, and duration of exposure and/or treatment doses or sequence. Diagnosis of such peripheral neuropathy is often easier than treatment. A full anamnesis and regular clinical evaluation are necessary. Electrophysiological assessments may support the diagnosis, although their contribution remains insufficient. Complex clinical features may require a specialized neurological assessment within the context of a multi-disciplinary approach. Finally, early detection of peripheral neuropathy and the use of dose adjustment algorithms as in the case of bortezomib, should help reduce the side effects while maintaining anti-tumor efficacy.

show abstract

Thalidomide-induced neuropathy

Abstract: Thalidomide induces a dose-dependent sensorimotor length-dependent axonal neuropathy; it should be judiciously used with close neurologic monitoring.

Cited by 180 publications

References 27 publications

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

Contact Info

Product

Resources

About